Alma D Campos-Parra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8019123/publications.pdf

Version: 2024-02-01

26 papers 1,134 citations

430874 18 h-index 26 g-index

26 all docs 26 docs citations

26 times ranked

2085 citing authors

#	Article	IF	CITATIONS
1	Crosstalk Between Long Non-coding RNAs, Micro-RNAs and mRNAs: Deciphering Molecular Mechanisms of Master Regulators in Cancer. Frontiers in Oncology, 2019, 9, 669.	2.8	184
2	Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Journal of Thoracic Oncology, 2015, 10, 838-843.	1.1	156
3	Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America. Journal of Thoracic Oncology, 2011, 6, 1955-1959.	1.1	113
4	The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer, 2015, 87, 169-175.	2.0	81
5	Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology, 2011, 77, 987-995.	1.1	61
6	Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. European Respiratory Journal, 2014, 43, 1439-1447.	6.7	55
7	MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review). Oncology Reports, 2016, 35, 3-12.	2.6	50
8	Clinical and Pathological Characteristics, Outcome and Mutational Profiles Regarding Non–Small-Cell Lung Cancer Related to Wood-Smoke Exposure. Journal of Thoracic Oncology, 2012, 7, 1228-1234.	1.1	48
9	Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 2711.	4.1	43
10	KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 33-40.	1.3	39
11	Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. International Journal of Molecular Sciences, 2017, 18, 1182.	4.1	39
12	Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN–AKT axis. Cancer Cell International, 2019, 19, 80.	4.1	38
13	A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumor Biology, 2017, 39, 101042831770289.	1.8	29
14	HypoxamiRs Profiling Identify miR-765 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells. Frontiers in Oncology, 2019, 9, 381.	2.8	25
15	MicroRNA-125 modulates radioresistance through targeting p21 in cervical cancer. Oncology Reports, 2018, 39, 1532-1540.	2.6	23
16	Comprehensive transcriptome analysis identifies pathways with therapeutic potential in locally advanced cervical cancer. Gynecologic Oncology, 2016, 143, 406-413.	1.4	22
17	EhNCABP166: A nucleocytoplasmic actin-binding protein from Entamoeba histolytica. Molecular and Biochemical Parasitology, 2010, 172, 19-30.	1.1	20
18	Identification of miRNA Master Regulators in Breast Cancer. Cells, 2020, 9, 1610.	4.1	20

#	Article	IF	CITATIONS
19	Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer. Journal of Cancer, 2016, 7, 1632-1644.	2.5	18
20	miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments. International Journal of Molecular Medicine, 2019, 44, 1267-1280.	4.0	16
21	BRCA mutations: is everything said?. Breast Cancer Research and Treatment, 2019, 173, 49-54.	2.5	12
22	Alternative splicing regulation in tumor necrosis factor‑mediated inflammation (Review). Oncology Letters, 2017, 14, 5114-5120.	1.8	10
23	Negative Regulation of Serine Threonine Kinase 11 (STK11) through miR-100 in Head and Neck Cancer. Genes, 2020, 11, 1058.	2.4	10
24	Molecular Differences between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers. Current Oncology, 2022, 29, 4689-4702.	2.2	10
25	A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population. Cancers, 2019, 11, 1246.	3.7	9
26	Entamoeba histolytica EhGEF1 structure and mutational analysis: New specific residues critical for function. Molecular and Biochemical Parasitology, 2009, 164, 118-125.	1.1	3